Mark Eisner

Mark Eisner is a highly experienced medical professional with an extensive background in biotechnology and pharmaceutical research and development. Based on his LinkedIn profile, he has held several leadership positions in prominent biotech companies.1

Career Highlights

Current Position: Mark Eisner is currently serving as the Chief Medical Officer at Sonoma Biotherapeutics, a position he has held since September 2023.1

Previous Roles:

• Executive Vice President and Chief Medical Officer at FibroGen, Inc. (December 2020 - September 2023)
• Senior Vice President and Global Head of Immunology, Infectious Disease, & Ophthalmology Development at Genentech (December 2018 - December 2020)
• Various leadership roles at Genentech, including Vice President and Global Head of Respiratory, Actemra, ID, and Metabolism Product Development (2010-2018)1

Education and Training

Mark Eisner has a strong educational background:

• MD from the University of Pennsylvania School of Medicine (1988-1992)
• AB in Human Biology from Stanford University (1984-1988)
• MPH in Epidemiology and Biostatistics from the University of California, Berkeley, School of Public Health (1999-2000)1

He completed his residency in Internal Medicine at the University of California, San Francisco, and served as Chief Medical Resident at Moffitt-Long Hospital.1

Professional Certifications

Mark Eisner is board-certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine by the American Board of Internal Medicine.1

Additional Involvement

• Scientific Advisory Board member at Aer Therapeutics, Inc. (September 2021 - Present)
• Former Board of Directors member for the American Thoracic Society (May 2009 - May 2011)
• Previously served on the Board of Directors for the Genentech Foundation (April 2019 - November 2020)1

Mark Eisner's career demonstrates a strong focus on clinical development, particularly in the areas of immunology, respiratory diseases, and infectious diseases. His experience spans across various therapeutic areas and includes strategic oversight of global clinical science groups.